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TreatmentThe autoimmune blistering diseases (AIBDs) are a group of heterogeneous skin diseases with autoantibodies di-
rected against structural proteins in the skin. A new interest in the female bias towards autoimmune diseases in
general has led to our attention to focus on how and why this female bias manifests in AIBD. The authors aim to
review and explore the various aspects of AIBD affecting females more than males, including the higher preva-
lence, worse quality of life, and complex management issues such as pregnancy and lactation.
© 2015 The Authors. Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The autoimmune blistering diseases (AIBDs) are characterized by
pathogenic autoantibodies directed at target antigens, whose function
is epidermal cell-to-cell or epithelium-to-dermis adhesion. Echoing au-
toimmune diseases in general, there is an overall female predominance
in themajority of AIBDs, including the pemphigus group andmost of the
pemphigoid group. Also, similar tomany other skin diseases, the quality
of life (QOL) of female patients with AIBDs is affected more than their
male counterparts, secondary to factors such as social misconceptions,
physical disability, and poormental health. Furthermore, there aremul-
tiple management issues that particularly affect females with AIBD, in-
cluding pregnancy and lactation. An awareness and understanding of
the female sex bias in AIBDs will ensure more appropriate diagnosis,
evaluation, intervention, and future research.
Generally, data available about autoimmune bullous diseases are lim-
ited, and sex-speciﬁc data is even rarer. Available studies are almost in-
variably limited by small patient size, selection biases, unclear
diagnostic criteria, or unreliable outcome measures. This highlights the
importance of maintaining AIBD registries and conducting well-
designed epidemiological and QOL studies. In Australia, there is currently
an AIBD registry being developed and expanded with ongoing research
into the epidemiology andQOL of patientswith AIBD (Daniel et al., 2011).ved for thewriting of this paper.
estwith the content of thepaper.
).
Inc. on behalf of Women's DermatIn this article, the sex-speciﬁc epidemiology and etiology of autoim-
mune diseases will be reviewed as a whole, followed by each AIBD in
turn, as the sex bias in eachAIBD varies. Then, the key factors underlying
the detrimental impacts of AIBDs onwomen’s QOLwill be explored and
explained. Subsequently, various management issues in pregnancy
and lactation will be discussed, with the focus on disease course and
treatment safety.Epidemiology and etiology
Sex bias in autoimmune diseases
The autoimmune diseases include over 70 chronic disorders, and are
well known to be generally more prevalent in women (Whitacre,
2001). Certain autoimmune diseases showan enormous sex bias, with fe-
males representing over 85% of cases of Addison’s disease, systemic lupus
erythematosus (SLE), Sjogren’s syndrome, and thyroiditis. Meanwhile,
other autoimmune diseases show a relatively weaker sex bias, with fe-
males representing 60–75% of patients, such as rheumatoid arthritis
(RA) and multiple sclerosis (MS) (Whitacre et al., 1999). As patients
with one autoimmune disease are more likely to have another autoim-
mune disease, the female predominance of autoimmune diseases is likely
furthermultiplied (Humbert et al., 1989). In addition to disease incidence,
the age of onset for many autoimmune diseases, including SLE andMS, is
earlier in females (Markle and Fish, 2014; McCarty et al., 1995).
Hormonal, immunological, microbiomial, and epigenetic theories
may explain sex-speciﬁc autoimmunity. Sex hormones are reported to
affect the susceptibility to autoimmune diseases. Clinically this isologic Society. This is an open access article under the CC BY-NC-ND license (http://
Fig. 2. Exfoliative scales and erosions on the chest of a female patient with pemphigus
foliaceus.
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cycle, pregnancy, andmenopause correlating to varied incidences of auto-
immune diseases in females. Some preexisting autoimmune diseases,
such as RA andMS, tend to remit in pregnancy and relapse in the postpar-
tum period (Markle and Fish, 2014). Studies have shown that testoster-
one has a protective effect and estrogen has a stimulatory effect on the
immune system (Ahmed and Penhale, 1982; Bebo et al., 1998; Harbuz
et al., 1995; Voskuhl et al., 1996). These effects may have been secondary
to sex hormone–dependent modulation of plasmacytoid dendritic cells’
function, evident by in vivo mice models (Calippe et al., 2008; Seillet
et al., 2012). Another explanation proposedwas that estrogenmay direct-
ly stimulate macrophages through ERα, and thereby augmenting the im-
mune response (Calippe et al., 2008). Furthermore, higher natural killer T-
cell numbers were observed in women as compared with men, with the
effects of androgen and ERα exposure on its functioning elucidated by
mice models (Gourdy et al., 2005; Sandberg et al., 2003).
Hormonal status of the host may also be shaped by microbiome
composition, which then reciprocally exerts inﬂuence over sex hor-
mone levels (Markle and Fish, 2014; Yatsunenko et al., 2012). Further-
more, the X chromosome has been shown to contain a large quantity
of immune-related genes, leading to theories suggesting sex-speciﬁc
epigenetic mechanisms for autoimmunity (Markle and Fish, 2014).
Pemphigus
Pemphigus is an uncommon group of AIBDs with an overall female
predominance. Its main types include pemphigus vulgaris (PV), account-
ing for 70% of total pemphigus cases, and pemphigus foliaceus (PF), ac-
counting for 15–20% of total pemphigus cases. Other, less common types
include paraneoplastic pemphigus, drug-induced pemphigus, pemphigus
herpetiformis, and pemphigus erythematosus. Immunopathologically, it
is characterized by autoantibodies of mainly IgG4 subclass targeted at
the epidermal intercellular adhesion glycoproteins, desmoglein 1 (Dsg1),
and desmoglein 3 (Dsg3). Clinically, it is manifested in patients aged 20
to 40 years and is characterized by ﬂaccid blisters and erosions of the
skin and mucous membranes (Figs. 1 and 2).
Multiple medium-to-large epidemiological studies have been con-
ducted for pemphigus. Epidemiological data from the United
Kingdom, Macedonia, Greece, Croatia, Italy, Bulgaria, France, Finland,
South Africa, Tunisia, Mali, China, Taiwan, Turkey, Iran, Korea, and
Kuwait have shown that pemphigus tends to bias females (Table 1)
(Aboobaker et al., 2001; Alsaleh et al., 1999; Bastuji-Garin et al., 1995;
Hietanen and Salo, 1982; Huang et al., 2012; Langan et al., 2008;
Ljubojevic et al., 2002; Mahe et al., 1996; McPherson and Venning,
2011; Micali et al., 1998; Michailidou et al., 2007; Seo et al., 2003;
Tsankov et al., 2000; Uzun et al., 2006; Zhu et al., 2014). The only excep-
tion was a relatively small study from the United States showing a
female-to-male ratio of 1.0 (Woldegiorgis and Swerlick, 2001). When
compared among continents, there were consistent female-to-maleFig. 1. Debilitating shallow oral erosions in a female patient with pemphigus vulgaris.ratios ranging between 1.1 and 2.3 in studies conducted in Europe and
Asia, and PV was almost always the dominant form in these studies.
The ratios were much higher in studies conducted in Africa; for exam-
ple, Mali and Tunisia had female-to-male ratios of 4.0 and 4.1, respec-
tively (Bastuji-Garin et al., 1995; Mahe et al., 1996). These were likely
inﬂuenced by the high incidence of endemic PF in these countries,
which may have a much higher prevalence in young women (Bastuji-
Garin et al., 1995). Limitations to our current knowledge of pemphigus
sex ratios include its epidemiology in Oceania and North America.
Also, no conclusion can be drawn regarding age-speciﬁc sex ratios of
pemphigus given the limited number of identiﬁed cases to date
(Marazza et al., 2009).
Pemphigus vulgaris
Pemphigus vulgaris has a female predominance, evidenced by female-
to-male ratios of 1.4, 2.3 and 1.62, respectively, in PV-only epidemiological
studies conducted in China, Greece, and Israel (McPherson and Venning,
2011; Michailidou et al., 2007; Pisanti et al., 1974). Pemphigus vulgaris
also echoes the pattern that autoimmune diseases occur more frequently
in patients with another autoimmune disease and has associations with
the female-predominant thyroid diseases and rheumatoid arthritis
(Ameri et al., 2013; Gupta et al., 2011; Ljubojevic and Lipozencic, 2012;
Svecova et al., 2014). Worsened outcome of PV has also been associated
with females, as one recent analysis showed that the HLA alleles
DRB1*04:02 and DQB1*03:02 were associated with severe PV, and
DQB1*03:02 was found more frequently in female patients than in males
(Svecova et al., 2014). However, no epidemiological studies to date have
evidenced the association of sex with this genetic predisposition.
Pemphigus foliaceus
There is a characteristic female predominance found in the Tunisian
subtype of PF, especially amongst youngwomen. Pemphigus foliaceus is
categorized into sporadic PF and endemic PF. The latter is also known as
fogo selvagem, which includes Tunisian, Brazilian, Peruvian-Amazon,
and Columbian pemphigus. Tunisian pemphigus was found to have a
female-to-male ratio of 4.1; an overall earlier onset, with the mean
age of onset at 28 years; and an overall increased incidence as compared
with other forms of pemphigus, at 4 cases per million (Bastuji-Garin
et al., 1995, 2002;Morini et al., 1993). A case–control study of 68 female
pemphigus patients in Tunisia revealed the development of Tunisian
pemphigus is signiﬁcantly associated with traditional Tunisian lifestyle,
including contactwith ruminants, cutting up rawpoultry, Turkish baths,
and cosmetics (Bastuji-Garin et al., 2002). Another case series of 23
Tunisianpemphigus patients suspected the provoking role of pregnancy
in disease development, as Tunisia is a country where young women
have a high fecundity rate (Morini et al., 1993). On the other hand,
Brazilian pemphigus was found to have no sex predisposition, and Co-
lumbian as well as Peruvian-Amazon pemphigus were both found to
have a contrasting male predominance (Abreu-Velez et al., 2003;
Table 1
Reported female-to-male ratios of pemphigus in worldwide representative studies.
Country Cases Dominant form Years Female-to-male ratio
Europe
United Kingdom (Langan et al., 2008) 138 PV 1996–2006 1.93
Macedonia (McPherson and Venning, 2011) 133 PV 1990–2004 1.33
Greece (Northern region) (Michailidou et al., 2007) 129 PV 1985–2004 2.25
Croatia (Ljubojevic et al., 2002) 159 PV 1996–1998 2.0
Italy (Sicily) (Micali et al., 1998) 84 PV 1982–1996 1.6
Bulgaria (Soﬁa) (Tsankov et al., 2000) 74 PV 1980–1995 1.11
France (Bastuji-Garin et al., 1995) 87 PV 1985–1990 1.2
Finland (Hietanen and Salo, 1982) 44 PF 1969–1978 1.1
Africa
South Africa (Aboobaker et al., 2001) 112 PF 1987–1999 1.4
Tunisia (Bastuji-Garin et al., 1995) 198 PF 1986–1991 4.1
Mali (Mahe et al., 1996) 30 PF - 4.0
Asia
China (Northeast region) (Zhu et al., 2014) 221 PV 2001–2010 1.4
Taiwan (Huang et al., 2012) 853 PV 2002–2009 1.3
Turkey (Mediterranean region) (Uzun et al., 2006) 148 PV 1998–2004 1.35
Iran (Chams-Davatchi et al., 2005) 1209 PV 1984–2003 1.5
Korea (Seo et al., 2003) 51 PV 1993–2001 1.3
Kuwait (Alsaleh et al., 1999) 45 PV 1981–1996 2.0
Israel (Pisanti et al., 1974) 76 PV 1952–1972 1.62
America
United States (Southeast region) (Woldegiorgis and Swerlick, 2001) 30 PV 1992–1999 1.0
Fig. 3. Urticarial papules and plaques in a female patient with newly diagnosed bullous
pemphigoid.
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clear due to limited epidemiological data.
Pemphigoid
Pemphigoid diseases are the commonest group of AIBDs; they have an
overall female predominance, the extent ofwhich varies amongst its types.
Pemphigoid diseases are deﬁnedby the presence of autoantibodies against
distinct structural components of the dermal–epidermal junction. Within
the pemphigoid group are bullous pemphigoid (BP), mucous membrane
pemphigoid (MMP), pemphigoid gestationis (PG), linear IgA diseases
(LADs), and epidermolysis bullosa acquisita (EBA).
Bullous pemphigoid
Bullous pemphigoid (BP) is the commonest pemphigoid disease and
has a slight female predominance. It is immunopathologically charac-
terized by autoantibodies targeting BP180 and BP230, which aremolec-
ular constituents of the stratiﬁed epithelial hemidesmosomes (Liu et al.,
1993; Stanley et al., 1981). Clinically, it is manifested by pruritic urticar-
ial papules and plaques, progressing to form vesicles and tense subepi-
dermal bullae (Fig. 3). Elderly patients after the seventh decade are
typically affected. Medium-to-large epidemiological studies in Poland,
United Kingdom, Switzerland, Scotland, Germany, Italy, France, Kuwait
and Singapore have shown BP’s female-to-male ratios to range between
1.04 and 1.6 (Table 2) (Bernard et al., 1995; Gudi et al., 2005; Jung et al.,
1999; Langan et al., 2008); Marazza et al., 2009; Nanda et al., 2006;
Serwin et al., 2007; Wong and Chua, 2002). This female predominance
may partly be explained by the fact that female patients are more likely
than males to live to the elderly age in which BP develops, given their
higher life expectancy. Interestingly, however, exceptionally higher
female-to-male ratios of 5.1 and 1.91 are reported in Kuwait and
Poland. Both of these studies have patient mean ages below 70 years,
whereas other studies mostly have patient mean ages above 70 years.
This trend recurred in the Switzerland study, which had also evidenced
the incidence of BP to be higher in women until the age of 70 years,
but thereafter the incidence is higher in men (Marazza et al., 2009).
The reason for this age-speciﬁc trend in sex difference is unexplained.
Although the female sex has been associated with a slightly increasedincidence of BP, studies have not discovered the female sex to be associ-
ated with mortality rate or relapse rates of BP (Cai et al., 2014; Fichel
et al., 2014). Future research regarding age-speciﬁc sex predominance
of BP, as well as its epidemiology in America, Africa, and Oceania, may
be implicated.
Mucous membrane pemphigoid
Mucous membrane pemphigoid, formally known as cicatricial pem-
phigoid, is a female-predominant and rare subtype of pemphigoid. It is
immunopathologically characterized by autoantibodies against BP180,
as well as BP230, laminin 332, α6β4 integrin, and type VII collagen
Table 2
Reported female-to-male ratios of bullous pemphigoid in worldwide representative studies.
Country Cases Mean Age Years Female-to-male ratio
Europe
Poland (Serwin et al., 2007) 35 68.9F, 67.3M 2000–2006 1.91
United Kingdom (Langan et al., 2008) 869 80 1996–2006 1.59
Switzerland (Marazza et al., 2009) 140 77.2 2001–2002 1.3
Scotland (Gudi et al., 2005) 83 79.2 1991–2001 1.5
Germany (Jung et al., 1999) 94 79.3F, 76.1M 1989–1997 1.01
Italy (Cozzani et al., 2001) 32 74 1996–1997 1.46
France (Bernard et al., 1995) 69 82.4 1989–1994 1.48
Asia
Kuwait (Nanda et al., 2006) 43 65.2 1991–2005 5.1
Singapore (Wong and Chua, 2002) 59 77 1998–1999 2.0
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fested by subepidermal blisters of the mucous membranes (Fig. 4). The
female-to-male ratio of mucous membrane pemphigoid is reported to
be almost 2.0 (Schifter et al., 2010;Woo and Greenberg, 2008). Howev-
er, epidemiological studies evidencing this female predominance have
not been performed.
Pemphigoid gestationis
Pemphigoid gestationis (PG) is an uncommon female-exclusive
pemphigoid disease, with autoantibodies directed against BP180
NC16A. It was formerly known as herpes gestationis, a term coined by
Dr. John Milton in 1872 to describe a 45-year-old woman with a
herpetiform rash in four out of nine pregnancies (Black, 2003). Clinical-
ly, PG ismanifested by intensely pruritic and urticarial-alike red papules
and plaques that progress to large, tense, ﬂuid-ﬁlled blisters in two to
fourweeks’ time (Fig. 5). Its other names include dermatitismultiformis
gestationis and gestational pemphigoid. Recent advances have shown
PG to be immunopathologically and clinically similar to the pemphigoid
group of diseases; hence it was renamed as pemphigoid gestationis.
Since then, there have been several medium-sized case series on PG, al-
though large epidemiology studies have been limited.
Pemphigoid gestationis has an incidence of 1 case in 50,000 to
60,000 pregnancies (Al-Fouzan et al., 2006; Cobo et al., 2009). A recent
review found itmay be the second-most-commonAIBD overall after BP,
accounting for 9.75% of 41 AIBD cases in one study (Bertram et al.,
2009). Almost one half of the cases develop in primigravida women.
Pemphigoid gestationis commonly presents in the second or third tri-
mester of pregnancy, but 10% of PG cases may occur in women within
4 weeks of giving birth (Ambros-Rudolph et al., 2006; Jenkins et al.,
1999). In a study of 505 women with pregnancy-related dermatoses,
21 had PG; of these, 71% occurred in the third trimester and 29% in
the second semester. Although PG most commonly develops inFig. 4. Vesicles and bullae in the gingiva of a female patient with mucous membrane
pemphigoid.pregnancy, case reports also have shown it occurring in women with
trophoblastic tumors, hydatidiform mole, or choriocarcinoma (Jenkins
et al., 1999). Women with PG are also more likely to have other
female-predominant autoimmune diseases, including Graves’ disease,
Hashimoto’s thyroiditis, and pernicious anemia. This can be partially ex-
plained by the presence of HLA-DR3 and DR4 antigens in PG, as these
were found to be independently associatedwith other autoimmunedis-
eases including autoimmune thyroiditis and pernicious anemia
(Shornick and Black, 1992).
Female sex hormones likely play a key role in PG disease course.
Pemphigoid gestationis has been reported to ﬂare after the use of oral
contraceptives and during menstruation. Progesterone, a hormone
that is raised at the end of pregnancy but plummets after the delivery
of the baby, depresses antibodies production (Da Silva, 1999). This
could explain the predelivery improvement in PG and its postpartum
ﬂare. On the other hand, estrogen, a hormone in oral contraceptives, en-
hances antibody production, which could explain the ﬂare after admin-
istration of oral contraceptives (Intong and Murrell, 2011).
Epidermolysis bullosa acquisita
Epidermolysis bullosa acquisita is a rare, female-predominant, and
phenotypically heterogeneous subtype of pemphigoid characterized
by autoantibodies against type VII collagen. Three studies so far have
speciﬁcally studied epidermolysis bullosa acquisita, and combined
data with a total of 83 cases revealed that its female-to-male ratio is
1.56 (Buijsrogge et al., 2011; Kim et al., 2011; Zumelzu et al., 2011).
Linear IgA disease
Linear IgA disease is a very rare subtype of pemphigoid with scarce
epidemiological data regarding sex-bias in its incidence. It is
immunopathologically characterized by linear binding IgA mainly af-
fecting BP180. Clinically, it is characterized by either annular blistersFig. 5.Urticarial plaques and grouped vesicles on the lower leg of a pregnant womanwith
pemphigoid gestationis.
Fig. 6.Annular plaqueswith raised and erodedmargins in a female patientwith linear IgA
disease.
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epidemiological studies conducted in Kuwait, Iran, Singapore, and
Tunisia with 1,711 AIBD patients in total had 27 cases of linear IgA dis-
ease. Out of these, 14 cases were male and 13 were female, equaling a
male-to-female ratio of 1.07 (Daneshpazhooh et al., 2012; Nanda
et al., 2004; Wong and Chua, 2002; Zaraa et al., 2011).
Dermatitis herpetiformis
In contrast to pemphigus and pemphigoid diseases, the evidence for
sex predominance in dermatitis herpetiformis (DH) has been conﬂict-
ing. Dermatitis herpetiformis has been shown to associate closely with
celiac disease, as both conditions are mediated by IgA autoantibodies
targeting the autoantigen transglutaminase. Although a small study
has reported that DH has a male-to-female ratio ranging from 1.5 to 2,
the opposite of this was found in a larger study of celiac disease,
which has a female-to-male ratio ranging from 2 to 4.1 (Llorente-
Alonso et al., 2006). The conﬂicting ﬁndings from the two studies
prompt further research regarding DH’s epidemiology.
Stevens–Johnson syndrome/toxic epidermal necrolysis spectrum
Toxic epidermal necrosis (TEN), Stevens–Johnson Syndrome (SJS),
and SJS/TEN overlap are life-threatening, typically drug-induced blister-
ing skin reactions affecting N 30%, b 10%, and 10–30% of total body sur-
face area, respectively. It has been proposed that there are autoimmune
mechanisms underlying its pathogenesis, with antigen-induced T-cell
activation leading to keratinocyte apoptosis (Schwartz et al., 2013).
Toxic epidermal necrosis has been shown to be more female-
predominant, though SJS may require more epidemiological studies to
conﬁrm if there is a sex predilection. A large study in France involving
253 TEN patients has found TEN to have a female-to-male ratio of 1.58
(Roujeau et al., 1990). This female predominance is conﬁrmed by
medium-size studies in India (25 patients) and Germany (40 patients)
showing female-to-male ratios of 2.57 and 1.22, respectively
(Sanmarkan et al., 2011; Weinand et al., 2013). However, regarding
SJS, its female-to-male ratios have been inconsistent in the limitednum-
bers of SJS-only studies performed so far, varying from 0.61 to 1.37
(Limpawattana et al., 2014; Sanmarkan et al., 2011). The female pre-
dominance in TEN, but not in SJS, has been unexplained so far.
Quality of life
AIBDs can have signiﬁcant impacts on the patient’s QOL. Like many
other skin diseases, the QOL of females with AIBD was found to be af-
fected more than the QOL of males in several studies to date (Paradisi
et al., 2009, 2012; Sampogna et al., 2006). The signiﬁcant impacts ofAIBDs on QOL are due to factors such as time spent on treatment, ﬁnan-
cial burden, social misconceptions, physical discomﬁt and limitations,
and poor mental health (Chee and Murrell, 2011; Sebaratnam et al.,
2012). Out of those, the last three factors were found to affect women
much more than men in various studies. Between the two main groups
of AIBDs, pemphigus has been shown to lead to a worse QOL with a Der-
matology Life Quality Index (DLQI) score of 10 (compared to pemphigoid
with a DLQI score of 6.92), possibly due to the rarity of mucosal involve-
ment in pemphigoid (Mayrshofer et al., 2005). Overall, pemphigus QOL
studies have been more frequently conducted than pemphigoid studies.
This may be partially explained by the fact that pemphigus is associated
with a worse QOL. Another explanation of the dearth of QOL studies in
pemphigoid could be that QOL questionnaires are more difﬁcult to ad-
minister in bullous pemphigoid patients, given their advanced age.
Measurement of QOL in AIBDs is of utmost importance, with signif-
icant recent efforts made into its research and developments. When
conducting most QOL studies in AIBD patients, generic QOL measures
such as the Medical Outcome Study 36-item Short-form Survey (SF-
36) or skin-disease generic QOL measures, such as the Skindex-17,
Skindex-29, or DLQI, have been used. In some studies, oral-health ge-
neric QOL measures such as Chronic Oral Mucosal Diseases Question-
naire (COMDQ) or psychiatric generic measures such as the 12-item
General Health Questionnaire (GHQ-12) have also been used. However,
none of those measures were disease-speciﬁc until the development of
the Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire
and the Treatment Autoimmune Bullous Disease Quality of Life
(TABQOL) questionnaire by the Murrell group (Sebaratnam et al.,
2013; Tjokrowidjaja et al., 2013). The ABQOL and TABQOL have both
been shown as valid and reliable instruments for measuring QOL and
treatment burden, respectively, in AIBDs.
Physical andmental factors are key contributors to theworseQOLof fe-
maleswith AIBDs as comparedwithmen. A study by Paradisi et al. (2009)
was conducted using the Skindex-29, the GHQ-12, and the SF-36 to evalu-
ate the QOL in 139 pemphigus patients in Italy. The study found that
women had worse physical and mental domain scores than men in the
Skindex-29 and the GHQ-12. For the Skindex-29, women scored 41, 41,
and36 compared tomen’s 31, 31, and 29 in its three components of symp-
toms (p= 0.01), emotions (p= 0.02), and social functioning (p N 0.05),
respectively. For the GHQ-12, which measured psychological distress,
42.9% ofwomen scoring≥ 4, compared to only 34.7% ofmen. No statistical
signiﬁcance analysiswas reported for theGHQ-12 results. Thisﬁndingwas
conﬁrmed in other diseases such as psoriasis and heart failure, where
women also reported more physical disability, worse pain, more symp-
toms, and more psychological issues than men with the same disease se-
verity (Emery et al., 2004; Sampogna et al., 2006).
The poorer physical scores in female pemphigus patients compared
with theirmale counterpartsmay be partly explained by the oral lesions
in pemphigus. A QOL study by Rajan et al. (2014) was conducted using
the COMDQ in 70 patients with chronic oral mucosal lesions, which in-
cluded 9 pemphigus patients. The study showed thatwomen scored sig-
niﬁcantly worse in pain and functional limitation: 21.44 for women
versus 16.14 for men. The pain and functional limitations may have sig-
niﬁcant subsequent implications for women, as this domain has been
found to relate to poor eating habits, interpersonal relationships, ap-
pearance, and self-image (Slade et al., 2004).
Due to symptomatic and psychosocial factors, the QOL of females
was found to be more affected than males even when their disease ac-
tivity was quiescent (Tabolli et al., 2014). A study was conducted by
Tabolli et al. (2014) using the Skindex-17 and the GHQ-12 in 203 pem-
phigus patients. The authors compared the QOL of 156 patients with ac-
tive disease and 47patientswithquiescent disease. The47patientswith
quiescent disease had no active bullae or erosions, and had Physical
Global Assessment scores as well as Ikeda scores of 0. The study found
that females in the active and quiescent disease groups both scored
higher than males in the symptoms and psychosocial components of
the Skindex-17 and the GHQ-12. More than 20% of the patients in the
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pemphigus. The item of Skindex-17 with smallest difference between
patients with active and quiescent disease was that of “I tend to do
things bymyself.”Hence, it is likely that pemphigus had not only caused
patients to do things by themselves when it was active, but also caused
them to continue having the same behavioral pattern after remission.
This may have affected females more given their worse QOL scores.
Quality of life is amultifactorial construct consisting of physical factors
as well as personality, expectations, socioeconomic and marital status,
and religious experience (Both et al., 2007). The worse QOL of females
with AIBDs has also been found to be due to social misconceptions, poor
self-image, and limited marriage prospects (Terrab et al., 2005). A study
by Terrab et al. (2005)was conductedusing the SF-36 aswell as questions
about the impact of pemphigus on self-perception, social relationships,
and behavior to explore the QOL of 30 patients with pemphigus in
Morocco. The study revealed that in Morocco, pemphigus was believed
to be linked to cultural taboos such as poor hygiene and unconventional
sexual practices, and would also be deemed incurable if drug-resistant.
Young women were particularly affected by limited marriage prospects,
which may further debilitate their psychosocial functioning.
In SJS/TEN, theQOLof females is likely compromised by itswell-known,
long-standing ocular and gynecological complications, which are likely
underestimated in its prevalence. A study by Haber et al. (2005) was con-
ducted using the SF-36 and DLQI in 13 patients admitted with TEN, 38 ±
27months after their hospital discharge. The study found the TEN patients'
SF-36 scoreswere signiﬁcantlyworse than thenormalpopulation, although
no sex-speciﬁc analysis was performed on the small study population. Oc-
ular complications occurred in 77% of patients, with the most common
symptoms being chronic sensitivity and dry eyes. Gynecological complica-
tions, which included vaginal adhesions and dyspareunia, were less fre-
quently observed than ocular complications, and occurred in two out of
eight female patients. Despite its lower prevalence, the signiﬁcant impact
of the TEN-related gynecological sequelae on QOLwas explored in another
retrospective study conducted by Meneux et al. (1998) in 40 female pa-
tients with TEN. The study found ﬁve patients had chronic gynecological
complications, and all of them had their sexual activities affected. Two pa-
tients with exclusive vulva sequelae, both of whom were younger than
30 years of age and nulliparous, completely avoided intercourse, which
may subsequently compromise their future relationships.Management issues
Pregnancy
Pregnancy and giving birth is a pivotal part of a woman’s life. How-
ever, for women with an AIBD, pregnancy raises several complicated
management issues including ﬂuctuating disease course, prudency re-
quired with investigations, treatment limitations, and the preference
for a vaginal delivery.
In a fertile woman with an established AIBD, pregnancy planning is
believed to improve pregnancy outcomesdue to the above issues. Precon-
ception counseling should be initially conducted in close collaboration
with the patient’s obstetrician and family doctor, highlighting the difﬁcul-
ties and importance of achieving disease control during pregnancy. This
should then be frequently revisited with any affected fertile woman
(Braunstein and Werth, 2013). Pregnancy should be planned to occur at
times of low disease activity so that certain contraindicated medications,
such as mycophenolate or rituximab, can be stopped or replaced prior to
conception with safer options such as dapsone, cyclosporine, IVIG, and
azathioprine (McPherson and Venning, 2011). Shorter period follow-up
appointments should be made throughout the pregnancy planning. Dis-
ease activity should be monitored clinically with a validated outcome
measure such as the Autoimmune Bullous Disorder Intensity Score
(ABSIS), Pemphigus Disease Area Index (PDAI), or Bullous Pemphigoid
Disease Area Index (BPDAI), and serologically with autoantibody titers,when available (Murrell et al., 2012; Pfutze et al., 2007; Rosenbach
et al., 2009).
An AIBD’s disease coursemay ﬂuctuate during pregnancy. This is be-
cause pregnancy itself is a speciﬁc immune state with dramatic hor-
monal changes in not only estrogen and progesterone, but also
cortisol, norepinephrine and dehydroepiandrosterone (McPherson
andVenning, 2011). Partly under the inﬂuence of suchhormonal chang-
es, immunological transformations occur in the mother to accommo-
date the genetically different fetal tissue, leading to varied AIBD
severity. Some AIBDs, such as pemphigoid gestationis, have their initial
onset associated with pregnancy, while other preexisting AIBDs may
improve or ﬂare during pregnancy or postpartum (Table 3). Pemphigus
vulgaris tends to improve during pregnancy but not until the third tri-
mester, and then ﬂares postpartum (Kardos et al., 2009). Associated
neonatal PV may occur, but is transient and easily treated (Campo-
Voegeli et al., 2002; Chowdhury and Natarajan, 1998). Pemphigus
foliaceus tends to have a variable course and associated neonatal PF is
extremely rare. On the other hand, BP is very rare in pregnancy, as it
mainly affects the elderly population.Meanwhile, LAD usually improves
in pregnancy and typically remits during the second trimester, but may
later relapse during the postpartum period (Collier et al., 1994).
Investigations including skin biopsies should be performed with
prudency in the pregnant woman. While in established AIBD there is
minimal need for a skin biopsy, in a newly presentedwoman, skin biop-
sies for histopathology and direct immunoﬂuorescence are traditionally
needed for diagnosis. In this case, it is important to ensure previous in-
vestigation results have been sought and to consider the individual’s cir-
cumstance prior to biopsying. This is because it is believed that there
may be a small risk of prilocaine fetal methemoglobinemia and uterine
blood ﬂow disruption that could happen secondary to local anesthetics
use during the skin biopsy (Hrgovic, 1990; Nau, 1985; Voorbrood et al.,
1982). Meanwhile, newer and safer diagnostic methods, including
enzyme-linked immunosorbent assay (ELISA) of BP180 and desmoglein
1 and 3 autoantibodies, indirect immunoﬂuorescence, and biochip immu-
noﬂuorescencemicroscopy, should be considered as potential alternatives
to biopsying (Russo et al., 2014; Sardy et al., 2013; Tampoia et al., 2012).
Treatment for AIBD in pregnancy is often required, but choice of
medication presents a challenge due to safety concerns. In general, sci-
entiﬁc evidence is limited due to the rarity of AIBDs and the exclusion
of pregnant woman from most drug trials. The current guidelines from
the United States Food and Drug Administration (FDA) and the
Australian Drug Evaluation Committee (ADEC) for common AIBD treat-
ments’ safety in pregnancy are summarized in Table 4, with relevant
recommendations from various studies (Murase et al., 2014).
Topical corticosteroids have been reviewed inmultiple large studies,
including a Cochrane review, and have not been shown to link to severe
adverse outcomes in pregnancy (Chi et al., 2009, 2010). However, very
potent topical corticosteroids may be associated with fetal growth re-
strictions. Oral corticosteroids are relatively safe butmay lead to serious
adverse outcomes in larger doses. Studies have shown oral corticoste-
roid use to lead to a three-fold increased risk of orofacial clefts in the
third trimester, aswell as possible associationswith premature delivery,
prematuremembrane, intrauterine growth retardation, gestational dia-
betes, hypertension, preeclampsia, and eclampsia (Carmichael et al.,
2007; Park-Wyllie et al., 2000). As such, experts recommend clinicians
to avoid using oral corticosteroids over 20 mg per day in pregnant pa-
tients (Murase et al., 2014). In this case, other anti-inﬂammatory or im-
munosuppressive therapies may be considered as an alternative.
Out of the other anti-inﬂammatory and immunosuppressive thera-
pies for AIBD, the relatively safer options in pregnancy would be dap-
sone, cyclosporine, IVIG, and omalizumab, although conclusive
evidence has been limited (Braunstein and Werth, 2013; McPherson
and Venning, 2011; Murase et al., 2014; Yu et al., 2014). These safer op-
tions would be useful for refractory AIBD in pregnancy. Azathioprine is
considered the best second-line alternative to corticosteroids, although
it has been reported to occasionally associate with preterm and low-
Table 3
The disease course of various more common autoimmune blistering diseases and associated adverse outcomes during pregnancy.
AIBD type Disease course in pregnancy Adverse outcomes Neonatal blistering disease
Pemphigus vulgaris May improve in the third trimester of
pregnancy but ﬂares postpartum
Adverse outcome in up to 10% of cases in one case series,
associated with poor disease control.
Risk for preterm birth in severe disease.
Transient and easily treatable
Pemphigus foliaceus Variable course Minimal Extremely rare
Bullous pemphigoid Rarely seen in pregnancy Not reported Not reported
Linear IgA disease May improve in the second trimester
but ﬂares postpartum
Minimal Not reported
Pemphigoid gestationis Typically occurs in second to third trimester Increased risks for preterm birth,
small for gestational age,
and low birth weight
Extremely rare
Abbreviation: AIBD, autoimmune blistering disease
Sources: Goldberg et al., 1993; Kardos et al., 2009; McPherson and Venning, 2011
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be avoided, as it has been shown to potentially increase the risk of var-
ious adverse outcomes including miscarriage, microtia, and various
organ system abnormalities (Kim et al., 2013). Caution should also
apply to rituximab, as it is potentially associated with hemolytic abnor-
malities (Murase et al., 2014).
At the endof thepregnancy, thedeliverymethod in thepregnantAIBD
woman should be vaginal, as slowwound healingmay occurwith caesar-
ean delivery associated with corticosteroid use. This would need to be
discussed with the patient’s obstetrician (Clay and Pandya, 2011).Table 4
Guidelines and recommendations for the use of autoimmune blistering disease treatments dur
Dermatologic Medications Commonly Used in AIBD Pregnancy
FDA1 ADEC2 Recommendatio
Corticosteroids Topical C A, B3,
C
Use mild to mod
Oral C A May increase th
Anti-inﬂammatory Dapsone C B2 Associated with
(IV)
IVIG C - Limited evidenc
Systemic
immunosuppressives
Mycophenolate
mofetil
D D Contraindicated
Cyclosporin C C Relatively safe i
Azathioprine D D Not recommend
Rituximab C - Not recommend
Omalizumab B B1 Limited evidenc
1United States Food and Drug Administration (FDA) drug risk classiﬁcations
A: Clinical data show no evidence of risk to the fetus
B: Clinical data are limited or not available, but animal studies show no evidence of risk to the fe
effects to the fetus
C: Clinical data are not available and animal studies are not available, or clinical data are not av
D: Positive evidence of risk to the fetus from clinical data
X: Contraindicated based on animal studies or clinical data
2Australian Drug Evaluation Committee (ADEC) drug risk classiﬁcations
A: Extensive clinical experience in pregnant women and women of childbearing age has show
B:Humandata are lacking or inadequate. Limited use in pregnantwomen andwomenof childbe
on the human fetus.
B1: Animal experiments have not given evidence of an increased incidence of fetal damage; si
B2: Animal experiments are inadequate; similar to FDA category C
B3: Reproduction toxicity studies in animals have revealed an increased incidence of fetal dama
C: Drugs which, owing to their pharmacologic effects, have caused or may be suspected of caus
effects may be reversible.
D: Drugs which have caused, are suspected to have caused, or may be expected to cause, an in
X: Contraindicated in pregnancy
3Evidence levels
IA: Meta-analysis of randomized controlled trials
IB: Randomized controlled trials
II: Nonrandomized controlled studies and any quasi-experimental study
III: Comparative, correlational, case–control
IV: Expert reports/opinions or clinical reports
Adapted from Murase et al., 2014
Sources: Ahmed andGurcan, 2011; Armenti et al., 1994; Butler et al., 2014; Carmichael et al., 200
and Bowe, 1989.Lactation
Lactating women with an AIBD also face the issue of drug safety. Al-
though most medications are relatively safe in lactation period, it is im-
portant to be aware of mycophenolatemofetil, which is contraindicated
in lactating women (Table 4). It has been shown that mycophenolate
mofetil can be transferred into the milk of lactating rats. This exposure
could lead to adverse effects on neonatal health, increasing the risks of
infection and lymphoma (Butler et al., 2014). Also, potent topical ste-
roids should be avoided around the nipple area and rituximab shoulding pregnancy and lactation.
Lactation
ns (Evidence level3) Recommendations (Evidence level3)
erate over potent strengths (IB) Ok for use on nipples, except for Class I
(IV)
e risk of oral clefts in ﬁrst trimester (IV) Use b 3 weeks (IV)
hyperbilirubinemia/hemolytic anemia Avoid in G6PD/hyperbilirubinemia (IV)
e for safety (IV) Can be used safely (III)
(III) Avoid, likely enters milk (IV)
n studies on transplants patients (III) Evidence limited (IV)
ed (III) Monitor infant health (IV)
ed (III) Minimal data, avoid (IV)
e for safety (IV) Evidence limited (IV)
tus, or clinical data show no evidence of risk to the fetus, but animal studies show adverse
ailable, but animal studies show adverse effects to the fetus
n no increase in the frequency of malformations or other harmful effects on the fetus
aring age has shownno increase in the frequency ofmalformation or other harmful effects
milar to FDA category B
ge, the signiﬁcance of which is considered uncertain in humans; similar to FDA category C
ing, harmful effects on the human fetus or neonate without causing malformations. These
creased incidence of human fetal malformations or irreversible damage.
7; Chi et al., 2009; Hocking, 1968;Murase et al., 2014; Osadchy andKoren, 2011; Thornton
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phosphate dehydrogenase (G6PD) deﬁciency.Summary
AIBDs have a female bias and are associated with higher disease in-
cidence, worse QOL, andmultiple management issues in pregnancy and
lactation. It is crucial to be aware of pemphigoid gestationis, which oc-
curs exclusively in females, aswell asmany of the pemphigus and pem-
phigoid group diseases, which are female-predominant. The QOL of
female patients, especially those with pemphigus, is worse than their
male counterparts due to social, mental, and disease factors. As clini-
cians it is important to screen for and then intervene on a more holistic
level to improve the female AIBD patient’s QOL. Management issues in
pregnancy and lactation also pose several challenges including varia-
tions in disease course and postpartum exacerbations, prudency re-
quired with investigations, and safety issues limiting treatment
options. No medication is safe beyond doubt, but low-dose corticoste-
roids, dapsone, cyclosporine, and IVIG are some of the safer options.References
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